14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $23.53 $28.69 Friday, 3rd May 2024 INSM stock ended at $25.55. This is 0.429% less than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 4.06% from a day low at $25.40 to a day high of $26.43.
90 days $23.53 $29.91
52 weeks $18.09 $32.00

Historical Insmed prices

Date Open High Low Close Volume
Mar 28, 2024 $27.22 $27.55 $27.01 $27.13 1 071 582
Mar 27, 2024 $27.02 $27.41 $26.71 $27.32 1 181 424
Mar 26, 2024 $27.29 $27.41 $26.95 $27.02 1 138 077
Mar 25, 2024 $26.50 $27.01 $26.19 $27.00 799 160
Mar 22, 2024 $26.57 $26.61 $26.02 $26.43 942 599
Mar 21, 2024 $26.83 $27.08 $26.34 $26.34 892 030
Mar 20, 2024 $26.00 $26.63 $25.90 $26.58 1 071 672
Mar 19, 2024 $26.08 $26.28 $25.98 $26.13 1 194 551
Mar 18, 2024 $25.78 $26.41 $25.52 $26.14 2 078 521
Mar 15, 2024 $26.17 $26.70 $25.59 $25.72 2 403 472
Mar 14, 2024 $27.84 $27.93 $26.10 $26.31 2 035 218
Mar 13, 2024 $27.35 $27.88 $27.11 $27.84 1 365 371
Mar 12, 2024 $27.00 $27.36 $26.82 $27.31 795 595
Mar 11, 2024 $27.84 $28.00 $27.07 $27.08 1 034 754
Mar 08, 2024 $28.18 $28.35 $27.25 $27.82 1 683 689
Mar 07, 2024 $28.20 $28.35 $27.53 $27.77 1 243 070
Mar 06, 2024 $28.07 $28.13 $27.50 $27.99 1 275 108
Mar 05, 2024 $28.11 $28.52 $27.34 $27.82 1 420 231
Mar 04, 2024 $28.22 $28.43 $27.30 $28.27 1 077 928
Mar 01, 2024 $27.91 $28.65 $27.89 $28.06 1 678 352
Feb 29, 2024 $28.59 $28.83 $27.63 $27.72 1 524 735
Feb 28, 2024 $28.97 $29.16 $27.84 $28.03 1 064 705
Feb 27, 2024 $29.27 $29.46 $28.35 $29.23 1 707 618
Feb 26, 2024 $27.29 $28.79 $27.20 $28.75 1 861 164
Feb 23, 2024 $27.41 $27.68 $26.72 $27.28 1 412 084
Click to get the best stock tips daily for free!

About Insmed

Insmed Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutr... INSM Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT